Feb 28 (Reuters) - Praxis Precision Medicines ( PRAX )

said on Friday an independent committee had recommended that its

tremor drug trial be stopped for futility, as the trial was

unlikely to meet the main goal.

Shares of the company fell 40% in premarket trading.

The Independent Data Monitoring Committee indicated that

some underlying assumptions of the statistical model might have

influenced this outcome and encouraged Praxis to explore

alternative analysis methods.

Praxis said it had decided to continue the trials to

completion given the advanced stage of patient enrollment and

the advice received from the committee.

The experimental drug, ulixacaltamide, is in late-stage

development for the treatment of essential tremor, a condition

that affects the nervous system and causes involuntary and

rhythmic shaking.

The company will explore different analysis methods for the

final dataset and expects to read out results in the third

quarter of 2025.